Hashem Taha

Hashem Taha

About

Detail

Go to Market | Storyteller | Tech x Bio Investor
Toronto, Ontario, Canada
Contact Hashem regarding: 
work
Full-time jobs

Timeline

work
Job
school
Education

Résumé

Jobs verified_user 0% verified
  • A
    Capital Formation and Investments
    Averin Capital
    Jun 2025 - Current (1 year 5 months)
    Underwriting 10x returns via growth investing in substantially de-risked healthcare technology companies with growing commercial traction.
  • Georgiamune Inc.
    Advisor - Strategy and Business Development
    Georgiamune Inc.
    Jan 2024 - Current (2 years 10 months)
    Market Intelligence, Portfolio Development, and Commercialization Strategy
  • Related Sciences
    Entrepeneur in Residence & Venture Creation
    Related Sciences
    Jan 2023 - Current (3 years 10 months)
    Therapeutic asset portfolio management, venture and capital formation, finance, BD partnerships.
  • Juvena Therapeutics
    Investor
    Juvena Therapeutics
    May 2022 - Current (4 years 6 months)
  • NFW
    Investor
    NFW
    Apr 2022 - Current (4 years 7 months)
  • Vectara
    Investor
    Vectara
    Jan 2022 - Current (4 years 10 months)
  • E
    Investor
    Eat Just, Inc.
    Mar 2021 - Current (5 years 8 months)
  • aiXplain
    Go to Market, Revenue Operations, and Partnerships
    aiXplain
    Aug 2020 - Current (6 years 3 months)
    Building a one-stop-destination for building and deploying adaptive multi-agent AI solutions.
  • aiXplain
    Investor
    aiXplain
    Aug 2020 - Current (6 years 3 months)
  • I
    Investor
    Aug 2020 - Current (6 years 3 months)
  • I
    Capital & Business Advisor
    Institutional Investors and Family Offices
    Jan 2020 - Current (6 years 10 months)
    1. Sourced and executed 3 buy and build specialty pharmaceutical manufacturing acquisitions in Ticino, Switzerland with a combined revenue of $200 M purchased at 60 % of net asset value. 2. Advised on the diligence and deal execution process on investments totaling $500 M. Notable investments: Collective Health, Color Genomics, Juvena Therapeutics, Recursion, Perfect Day, Modern Meadow, Natural Fiber Welding, LeoLabs, Kneron, Vectara, aiXplain, Soul Machines, Boost Security, Tonal, Ample, Atom, Reach Labs. Fund Creation: pi Ventures, Singularity Ventures. Notable co-investors: Mubadala Ventures, Canada Pension Plan Investment Board, Horizons Ventures, DCVC, Iconiq, Temasek, Blackstone, BMW iVentures, SoftBank Vision Fund
  • Perfect Day
    Investor
    Perfect Day
    Feb 2019 - Current (7 years 9 months)
  • LeoLabs
    Investor
    LeoLabs
    Jul 2018 - Current (8 years 4 months)
  • Kneron
    Investor
    Kneron
    Jun 2018 - Current (8 years 5 months)
  • Vectara
    Go to Market
    Vectara
    Apr 2022 - Jun 2023 (1 year 3 months)
    Making large language model (LLM) powered search available for everyone with cloud based APIs. Responsibilities: 1. Launched the company from stealth mode with $28 M in funding. 2. Setting product pricing and packaging strategy 3. Leading product marketing, content strategy development, and execution.
  • Transform VC
    Investor and Entrepreneur in Residence
    Transform VC
    Jan 2020 - Jun 2025 (5 years 6 months)
    Leading investments in biotech, techbio, computational sciences, AI/ML infra and developer tools. Founding GTM, BD, and finance / revenue operations executive at aiXplain and Vectara.
  • I
    Investment Associate
    Oct 2016 - Jan 2020 (3 years 4 months)
    In Colour Capital is a Toronto-based principal investment firm that invests across venture, growth equity, special situations, and buyout transactions across the globe. Responsibilities: 1. Led investment process (diligence, negotiation, and deal execution) on transactions totaling $250 M in renewable energy, novel materials, synthetic biology and agri technology, applied ML, and enterprise SaaS. 2. Co-led the creation of pi Ventures - India’s first applied AI/ML fund and developed the fund’s investment thesis around healthcare, logistics, and customer experience. 3. Managed all investor relations and communications of portfolio company performance updates via memos and conference call briefings.
  • University Health Network
    Research Scientist - Cancer Immunology
    University Health Network
    Sep 2016 - Nov 2018 (2 years 3 months)
    - Investigated the cytotoxicity profiles of different NK cell lines against a panel of blood and solid tumor targets in Dr. Armand Keating's lab. - Demonstrated the immunostimulatory function of natural product extracts in enhancing the anti tumor killing efficacy of NK cell lines. - Launched a seminar series covering the latest scientific, clinical, and commercial advances in cell and gene therapy.
  • Sunnybrook
    Research Student
    Sunnybrook
    Sep 2013 - Jun 2014 (10 months)
    - Developed a protocol to isolate, cultivate, and expand umbilical cord blood-derived MART-1 specific T memory stem cells for melanoma immunotherapy in Dr. Juan Carlos Zuniga-Pflucker's lab. The choice of younger T cells with stem cell like features addresses the core issues of short-lived antitumor immune responses, cell survival and engraftment, and therapeutic effect persistence.
  • INTERNATIONAL MEDICAL CENTER
    Clinical Intern--Cardiology and Cardiothoracic Surgery
    INTERNATIONAL MEDICAL CENTER
    Jul 2011 - Sep 2011 (3 months)
Education verified_user 0% verified
  • New York University
    Advanced Valuation Finance, General
    New York University
    Jan 2017
  • University of Toronto
    MASc. Biomedical Engineering
    University of Toronto
    Jan 2016 - Jan 2018 (2 years 1 month)
  • University of Toronto
    bachelor, Honours BSc. with High Distinction Immunology, Drug Development, Behavioral Psychology
    University of Toronto
    Jan 2010 - Jan 2014 (4 years 1 month)
This is a community-created genome.